STI Pharmaceuticals NewsFebruary 2006 STI Pharmaceuticals complete product development trials STI Pharmaceuticals complete a proof of concept study in 12 healthy volunteers at the University of Bern, Switzerland. This study confirmed that the cannabinoid combination of Delta-9 Tetrahydrocannabinol (Delta-9 THC) and Cannabidiol (CBD) are systemically deliverable via an asthma inhaler (pMDI). The principal investigator, Professor Rudolph Brenneisen, concluded that the inhaler was well tolerated with little evidence of psychotropic activity. Further studies are now planned in specific disease groups.
|
|
||||||||